This aligns with the results of Kurniawan et al. and Seo et al. who demonstrated that while AFP and PIVKA-II had similar individual diagnostic performance in differentiating HCC from nonmalignant CHB, their combined use significantly improved the diagnostic accuracy, particularly in cirrhotic patients [28,29]. Here, AFP is linked to hepatocellular carcinoma.